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INTRODUCTION
Today, women experience ten times more menstrual cycles than their 
ancestors did. Over the years menorrhagia has become an increasingly frequent 
complaint.   This  may be attributed to the increased availability  of effective 
contraception,  decreased tolerance of the inconvenience of menorrhagia and 
higher expectations of the health service.
The social and economic cost of menorrhagia is considerable.  Nearly 
28% of female population consider their menstruation excessive.  Nearly 10% 
of  employed women will  need  to  take time  off  work  because  of  excessive 
menstrual loss (Edmund M et al, 1994). Annually, 30% of hysterectomies are 
carried  out  for  menstrual  disturbances  alone  (Coulter  et  al,  BJOG,  1991). 
Menorrhagia  is  the  main  cause  of  iron  deficiency  anaemia  in  women  in 
developed countries (Beazly JM, 1992).
Thyroid  dysfunction  is  a  common cause  of   AUB and  accounts  for 
30-40% of cases (Koutras DA, 1997).  Thyroid disorders  are 10 times more 
common in women than men (Sisan et al,  1987).  Approximately 1% of the 
female  population  will  develop  overt  hypothyroidism  (Turnbridge  WMG, 
1977).  Abnormal  menstrual  cycles  are  occasionally  the  first  sign  of 
hypothyroidism or hyperthyroidism.(Wilansky DL, Griesman B, 1992).
The clinical objective is to detect and treat thyroid disease before the 
symptoms and signs are significant and intense.  Therefore the key to early 
diagnosis is to maintain a high index of suspicion and to readily screen for the 
presence of abnormal thyroid function.  Moreover, thyroid dysfunction is an 
easily  correctable  cause  of  AUB. Appropriate  treatment  is  rewarded by  the 
prompt return of normal menstrual cycles.
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AIM OF THE STUDY
The study is aimed at a cross-section of population presenting to the 
Department of Obstetrics and Gynaecology at the Government RSRM Lying-in 
Hospital,  Stanley  Medical  College  with  complaints  of  abnormal  uterine 
bleeding.  The study aims to ascertain the following:
1) Possibility of association between thyroid dysfunction and AUB in 
the reproductive age group (18-45 years).
2) To  study  the  thyroid  profile  in  different  types  of  AUB  in  the 
reproductive age group.
3) To establish if screening for thyroid abnormalities is justified using 
T4 and TSH.
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REVIEW OF LITERATURE
1. Gardner and Hill in 1927 showed an association between hypothyroidism 
and menorrhagia.
2. Goldsmith et al in 1952 found that 8 out of 10 patients with hypothyroidism 
had  ovulatory  failure  with  only  2  experiencing  normal  ovulation  and 
menses.
3. Rogers et al in 1958 stated that the most common abnormality observed by 
hypothyroid women is a change in the character of uterine bleeding and 
length of the cycle.
4. Scott in 1964 found that 56% of women with hypothyroidism had abnormal 
menstrual patterns with menorrhagia being the most common. 
5. Blum and Blum in 1972 have studied the relationship between subclinical 
hypothyroidism and menorrhagia.
6. Geenspan et al in 1975 advocated the empirical use of the thyroxine. But in 
1999,  Prentice  et  al  have  stated  that  the  empirical   use  of  thyroxine  is 
controversial.  They have condemned it and advocated the use of TRH in 
women with AUB and normal T3, T4, and TSH.  
7. Akande in 1975 stated that changes in FSH/LH ratios caused anovulatory 
cycles in hypothyroidism.
8. Andrew  Weeks  in  1987  in  his  study  of  650  women  with  menstrual 
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disturbances  at  the  Jessop  hospital  has  stated  that  hypothyroidism  is  a 
greatly underdiagonised cause of menorrhagia.
9. Keye WR, Yuen B Knopff  in  1976 have  stated that  hyperprolactinemia 
causing  luteal  phase  defect  is  asociated  with  less  severe  forms  of 
hypothyroidism. 
10. Robuschi et al in 1987 have stated that hypothyroidism increases with age 
and is more common in older women.  Upto 45% of thyroid glands from 
women  over  60  show  evidence  of  thyroiditis.  The  incidence  of  anti-
thyroglobulin antibodies is 7.4% in women over age 75 while 16.9% of 
women aged 60  and 17.4% of  women over  age  75  have  elevated  TSH 
levels.  In  women  admitted  to  geriartric  wards,  2-4  %  have  clinically 
apparent hypothyroidism.
11. Klee et al in 1987 have shown the significance and positive predictive value 
of TSH assay in thyroid function tests.  They are of opinion that TSH based 
testing  strategies  minimise  the  problem  of  abnormal  T4 study  and 
significantly reduce the number of TRH stimulation tests performed. 
12. Smith et  al  in 1987 showed an association between hypothyroidism and 
menorrhagia with development of an advanced form of Von Willebrands' 
disease  in  untreated  hypothyroidism.  The  hemostatic  defects  returned to 
normal with thyroxine supplementation.
13. Bleney et al in 1990 confirmed the findings of Smith et al.
14. Hingham in 1992 reported a case of hypothyroidism in which the menstrual 
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loss was measured. An initial loss of 480 ml decreased to 58 ml following a 
3 month treatment with thyroxine.
15. Wilansky et al in 1992 performed thyrotropin releasing hormone (TRH) test 
in 67 women who complained of excessive menstrual loss. All had normal 
levels of thyroxine and thyroid stimulating hormone (TSH).  They found 
that  22% had  abnormal  TRH  tests  and  they  treated  these  women  with 
thyroxine.  At follow up between 12 and 36 months later, all considered 
their menstrual loss to be normal.  In the 16 women with normal TRH tests, 
56% still complained of menorrhagia.
16. Blum  and  Blum  in  1992  studied  the  possible  relationship  between 
menorrhagia  and  occult  hypothyroidism  in  IUD-wearing  women.  They 
studied  40  women  with  menorrhagia  secondary  to  an  intrauterine 
contraceptive device.  They all had normal free thyroxine and TSH levels. 
The 10 patients who had the highest TSH levels were given a TRH test and 
all proved to have early hypothyroidism. All patients reported a significant 
improvement with thyroxine treatment.  This recent development deserves 
further study.
17. Danese MD et al in 1996 have stated that hypothyroidism is frequent 
enough to warrant consideration in most older women. They recommend 
screening with highly sensitive TSH assay every 5 years beginning at 
age  35  and  then  every  two  years  beginning  at  age  60   or  with  the 
appearance of any symptom suggesting hypothyroidism.
18. Chameron and Fraser in 1998 in their study on the clinical disorders of 
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the  endometrium  and  the  menstrual  cycle  have  stated  that  thyroid 
disorders are the most common endocrine abnormality associated with 
menstrual  disturbances.  Hypothyroidism  is  a  potent  cause  of 
menorrhagia which is amenable to treatment.
19. Shaw RW in 1999 conducted a large comparitive analysis to study the 
effect of thyroxine replacement on menstrual blood loss in hypothyroid 
patients.   There  was  a  relative  improvement  in  haemoglobin 
concentration and general condition of the patients.
20. Prentice et al - Medical Management of Menorrhagia - 1999 have stated 
that  all  women  with  unexplained  menorrhagia  should  be  tested  for 
thyroid dysfunction.
The review of literature suggests that there is a strong correlation between AUB 
and thyroid dysfunction.  It stands as an easily correctable cause of AUB.
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PHYSIOLOGY OF MENSTRUATION
Menstruation is a very recent phenomenon in the evolutionary time line. 
It occurs in very few species even among viviparous animals.  The diagnosis 
and  management  of  abnormal  menstrual  function  must  be  based  on  an 
understanding of the physiologic mechanisms involved in the regulation of the 
normal cycle.  Although the activity of the endometrium is directly controlled 
by the ovarian function and by the two hormones secreted by the ovary, the 
ovary itself is activated by the pituitary gland, the secretion of which is under 
the nervous control of the hypothalamus.
The normal human menstrual cycle can be divided into two segments : 
the ovarian cycle and the uterine cycle based on the organ under examination. 
The  ovarian  cycle  maybe  further  divided  into  follicular  and  luteal  phases, 
whereas the uterine cycle is divided into the corresponding proliferative and 
secretory phases.
(1) At the beginning of each monthly menstrual cycle, levels of gonadal 
steriods are low and have been decreasing since the end of the luteal 
phase of the previous cycle.
(2) With the demise of the corpus luteum, FSH levels begin to rise and a 
cohort of growing follicles is recruited.  These follicles each secrete 
increasing levels of oestrogen as they grow in the follicular phase. 
This, in turn, is the stimulus for uterine endometrial proliferation.
(3) Rising oestrogen levels  provide a  negative  feed back on pituitary 
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FSH secretion which begins to wane by the midpoint of the follicular 
phase.  Conversely,  LH  initially  decreases  in  response  to  rising 
estradiol  levels  but  late  in  the  follicular  phase  the  LH  level  is 
increased dramatically (biphasic response).
(4) At  the  end  of  the  follicular  phase  (just  prior  to  ovulation),  FSH 
induced LH receptors are present on granulosa cells and with LH 
stimulation, modulate the release of progesterone.
(5) After a sufficient degree of oestrogenic stimulation, the pituitary LH 
surge is triggered, which is the proximate cause of ovulation which 
occurs 24-36 hours later.  Ovulation heralds the transition to luteal-
secretory phase.
(6) The oestrogen level decreases through the early luteal  phase from 
just before ovulation until the midluteal phase when it begins to rise 
again as a result of corpus luteum secretion.
(7) Progesterone levels rise precipitously after ovulation and can be used 
as a presumptive sign that ovulation has occured.
(8) Both oestrogen and progesterone levels remain elevated throughout 
the life of the corpus luteum and then wane with its demise, thereby 
setting the stage for the next cycle.
(9) In  the  absence of  implantation,  glandular  secretion ceases  and an 
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irregular breakdown of the decidua functionalis occurs.  The result is 
a  shedding  of  this  layer  of  the  endometrium,  a  process  termed 
menses.
The Normal Menstrual Cycle
A normal menstrual cycle lasts from 21 to 35 days with 2 to 6 days of 
flow and an average blood loss of 20-60 ml. (Vollman RF, 1977 and Treloar 
AE,  1967).   However  studies  of  large  numbers  of  women  with  normal 
menstrual  cycles  have  shown  that  only  approximately  two-thirds  of  adult 
women have cycles lasting 21-35 days (Friedman E, 1977).  The extremes of 
reproductive life are characterised by a higher percentage of anovulatory or 
irregularly timed cycles ( Collett ME et al, 1954).
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DEFINITION OF MENSTRUAL CYCLE IRREGULARITIES
(1) Oligomenorrhea :
Infrequent,  irregularly  timed 
episodes of bleeding usually occuring 
at intervals of more than 35 days.
(2) Polymenorrhea :
Frequent  but  regularly  timed 
episodes of bleeding usually occuring 
at intervals of 21 days or less.
(3) Menorrhagia :
Regularly  timed  episodes  of 
bleeding that are excessive in amount 
(>  80  ml)  and duration  of  flow (>5 
days).
(4) Metrorrhagia :
Irregularly timed bleeding.
(5) Menometrorrhagia :
Excessive, prolonged bleeding 
that  occurs  at  irregularly  timed, 
frequent intervals.
(6) Hypomenorrhea :
Regularly  timed bleeding  that 
is decreased in amount.
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(7) Intermenstrual bleeding :
bleeding  (usually  not  of  an 
excessive  amount)  that  occurs 
between otherwise normal menstrual 
cycles.
(8) Amenorrhea :
Absence  of  menstruation  for 
three normal cycles or six months.
THE THYROID GLAND
Thomas Wharton in 1656, gave the thyroid gland its modern name.  For 
unknown reasons,  thyroid  disease  is  more  common in  women than in  men 
(Medvei VC, 1993).
Normal Thyroid Physiology
Thyroid hormone synthesis depends on an adequate supply of iodine in 
the diet.  It is absorbed as iodide and enters the thyroid under the influence of 
TSH. Within the gland iodide is oxidised to elemental iodine which is then 
bound to tyrosine.  Mono and di-iodotyrosines combine to form thyroxine (T4) 
and Tri-iodothyronine (T3) (Norman AW, Litwack G, 1987). These compounds 
are part of  the thyroglobulin molecule which serves as a storage depot for the 
thyroid hormone.  TSH induces a proteolytic enzyme that results in the release 
of iodothyronines into the bloodstream as thyroid hormone.  Removal of one 
iodine from the phenolic ring of T4 yields T3.
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One-third of T4 secreted each day is converted in the peripheral tissues, 
largely in the liver and kidney to T3 and about 40% is converted into inactive 
Reverse T3.  Although T4 in secreted at 20 times the rate of T3, T3 is responsible 
for most of the thyroid action in the body (Czarnocka B et al, 1985).
Mechanism of Thyroid Hormone Action
Thyroid  hormone  acts  by  binding  to  a  specific  nuclear  DNA bound 
thyroid hormone receptor (TR) usually as a heterodimer with the retinoid X 
receptor  (RXR)  at  specific  sequences  dictated  by  the  DNA  binding  site 
preferences of the RXR-TR complex.  T3 has a 15 fold higher binding affinity 
for TR than does T4 which explains its function as the active thyroid hormone 
(Brent GA, 1994).
Bound and Free fractions of Thyroid Hormones
Thyroid hormones present in circulation are mainly bound to proteins. 
Approximately  70%  of  thyroid  hormones  are  bound  to  thyroxine  binding 
globulin (TBG).  The remaining 30% is bound to thyroxine binding prealbumin 
and albumin.  The binding proteins have greater affinity for T4 and thus allow 
T3 to have a greater entry into the cells.  TBG is synthesised in the liver and the 
synthesis is increased by oestrogens.
Regulation of thyroid hormone secretion - Role of estrogens
Thyroid hormones regulate TSH secretion by supressing TRH secretion, 
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but primarily affect the pituitary sensitivity to TRH, by reducing the numbers 
of TRH receptors.  Pituitary secretion of TSH is very sensitive to changes in 
the circulating level of thyroid hormone.  A slight change in the circulating 
level of T4 will produce a many fold greater response in TSH.  TSH secreting 
cells are regulated by T4 but only after the T4 is converted to T3 in the pituitary 
cells.   Although  some  tissues  depend  mainly  on  the  blood  T3 for  their 
intracellular  T3,  the  brain  and  pituitary  depend  on  their  own  intracellular 
conversion of T4.
The measurement of T4 and TSH therefore provides the most accurate 
assessment of thyroid function.
The TSH response to TRH is influenced mainly by the thyroid hormone 
concentration in the circulation.  Estrogen increases the TRH receptor content 
in the pituitary.  Hence the TSH response to TRH is greater in women than in 
men and greater in women taking oral contraceptives.
The smallest doses of the TRH that are capable of producing an increase 
in TSH also increase the prolactin levels indicating a physiologic role for TRH 
in the control of prolactin secretion.
Thyroid Function Tests
Serum  thyroid  hormones  are  measured  by  radio-immunoassay. 
Conditions that elevate the TBG (pregnancy, oestrogen replacement, use of oral 
contraceptive pills,  hepatitis) necessitate measurement of T3 resin uptake for 
clarification.
(1) Free  Thyroxine  (FT4):  Assays  that  measure  free  T4 are  usually 
displacement  assays  using  an  autoantibody  to  T4.   The  result  is  not 
17
affected by changes in TBG and binding.
(2) Total Thyroxine (TT4): The total thyroxine, both the portion bound to 
TBG and the free unbound portion is measured by displacement assays 
and in the absence of hormone therapy and other illnesses estimates the 
thyroxine concentration in the blood.
(3) TSH  :  TSH is  measured  by  highly  sensitive  assays  than  can  detect 
concentrations as low as 0.01 µu/L.  This is a very sensitive indicator of 
thyroid hormone action at tissue level because it  is  dependent on the 
pituitary exposure to T4.   In the absence of hypothalamic or pituitary 
disease,  the  sensitive  TSH assays  will  provide  the  best  indication of 
excess  or  deficient  thyroxine.  Slight  changes  in  T4 are  reflected in  a 
many fold greater response in TSH. Transient changes in TSH are seen 
in  severe  systemic  illness,  psychiatric  illness,  adrenal  insufficiency, 
corticosteroid therapy, elevated hCG (Since hCG can stimulate the TSH 
receptor) and in any acute illness.
(4) Total T3 and Reverse T3 : These are rarely required for the accurate 
evaluation of a  patient  with an abnormal TSH level  and are  of  little 
value in clinical circumstances.  Serum T3 is almost always an indirect 
reflection of the serum T4 supply (Berghout A, 1994).
Other  tests  include  the  free  thyroxine  index  and  radioactive  iodine 
uptake.
THE LABORATORY EVALUATION
For  screening  purposes  or  when  there  is  a  relatively  low  clinical 
suspicion  of  thyroid  disease,  the  initial  step  is  to  measure  the  TSH  by  a 
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sensitive assay.  A normal TSH essentially excludes hypo / hyperthyroidism.  A 
high TSH requires  the  measurement  of  free  T4 to  confirm the  diagnosis  of 
hypothyroidism.  If the initial TSH is low, especially less than 0.08 µu/ml, then 
measurement of a high T4 will confirm the diagnosis of hyperthyroidism.  If  T4 
is normal, the T3 level is measured since some patients will have predominantly 
T3 toxicosis.
If T3 is normal it implies that thyroxine secretion is autonomous from 
TSH and this is called subclinical hyperthyroidism.  Some of these patients will 
eventually have increased T4 or T3 levels with true hyperthyroidism.
The algorithm represents a cost-effective and accurate clinical strategy.
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Sensitive TSH
High Normal Low
Free T4Free T4
Low Normal
Normal
Thyroid
Normal High
Free T3
Normal High
Hyper
thyroid
Subclinical
Hyper
thyroidism
Subclinical
Hypo
thyroidism
Hypo
thyroid
(Surks MI, Chopra IJ, Mariash CN, Nicoloff JT, Solomon, TH American Thyroid 
Association guidelines for use of laboratory tests in thyroid disorders, JAMA 263: 
1529,1990).
Role of Thyroid in Reproductive Physiology / Pathology
The following facts  emphasis the role of thyroid hormone in the female 
reproductive physiology.
(1) TSH receptors have been found on granulosa cells.
(2) T3 and T4 have been found in follicular fluids.
(3) T4 has  been  found  to  enhance  the  action  of  gonadotrophins  in 
luteinisation and progesterone secretion.
The  female  hormonal  milieu  and  its  potential  effects  on  immune 
surveillance undoubtedly play a role in the increased risk (10 fold) of women to 
develop autoimmune thyroid disease (Gaitan E et al, 1985 and Wenzel BE et 
al, 1987).  The immunoglobulins produced against the thyroid are polyclonal 
and the multiple combinations of various antibodies present combine to create 
the  clinical  spectrum of  autoimmune thyroid  diseases  that  affect  successful 
reproductive function.
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Foetal and neonatal period
Very few data exist regarding the role of the thyroid hormones in the 
reproductive system of the foetus.  No effective human studies are available 
Thyroid excess in mice is shown to cause early maturation of the reproductive 
tract and early opening of the vagina. Hypothyroidism in mice causes small 
ovaries  deficient  in  cholesterol.  No  change  has  been  observed  in  human 
foetuses.
Hypothyroidism
(1) Prepubertal / Pubertal
In  both  sexes,  thyroid  hormones  influence  sexual  development  and 
reproductive function.
Infantile  hypothyroidism,  if  untreated,  leads  to  sexual  immaturity. 
Juvenile hypothyroidism causes a delay in the onset of puberty followed by 
anovulatory cycles.
Paradoxically  primary  hypothyroidism  may  also  cause  precocious 
sexual development and galactorrhea.  (Kleinberg DL, New England J. Med. 
1977). The McCune Albright syndrome is characterized by hyperfunctioning 
endocrinopathies including hyper/hypothyroidism and sexual precocity, but the 
association  may  be  coincidental  (Albright  F,  Maine  MJ,  1938).  Precocious 
puberty with delayed bone age suggests primary hypothroidism. Serum TSH is 
increased,  T4 is  low and  galactorrhea  maybe  present  with  increased  serum 
prolactin (Honbo KS et al, 1978). Kindle et al have described a syndrome of 
precocious  menstruation,  galactorrhea  and  sella  enlargement  in  girls  with 
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juvenile hypothyroidism. 
2. In adult women
Severe  hypothyroidism  in  associated  with  diminished  libido, 
amenorrhea or anovulation (Grodstein F et al, 1993). Secretion of progesterone 
is inadequate and endometrial proliferation persists resulting in excessive and 
irregular  breakthrough  menstrual  bleeding.  These  changes  may  be  due  to 
deficient secretion of luteinizing  hormone. Rarely in primary hypothyroidism, 
secondary depression of pituitary function may lead to ovarian atrophy and 
amenorrhea.  Hypothyroidism appears to be associated with decreased fertility 
resulting  from ovulatory  difficulties,  and  spontaneous  abortions  may  result, 
although  many  pregnancies  are  successful.  (Lao  TTH  et  al,  1988  and 
Morimotoc et al, 1990).
The values for plasma gonadotrophins are usually in the normal range in 
primary hypothyroidism.  In postmenopausal women, levels are usually lower 
than  euthyroid  women  of  the  same  age  but  are  nevertheless  within  the 
menopausal range. This provides a valuable means of differentiating primary 
from secondary hypothyroidism  (Melmed S, Hershman J, 1982).
Myxedematous infiltration can produce enlarged, cystic ovaries (Kansen 
KA et al, 1997).
There may be a high incidence of early or potential hypothyroidism in 
women presenting with menorrhagia. Hypothyroidism can cause menorrhagia / 
polymenorrhea  -  these  symptoms  being  present  in  30  -  40% of  the  cases. 
22
(Koutras DA, 1997).
Metabolism of oestrogens in hypothyroidism
The metabolism of oestrogens is also altered. With respect to oestradiol 
and oestrone, hypothyroidism favours the metabolism of these steroids via 16-
α-hydroxylation over that via 2-oxygenation with the result that the formation 
of  oestriol  is  increased  and  that  of  2-hydroxyoestrone  and  its  derivative  
2- methoxyoestrone is decreased. The sex hormone binding globulin (SHBG) 
concentrations  in  plasma  is  decreased  with  the  result  that  the  plasma 
concentrations  of  both  testosterone  and  oestradiol  are  decreased,  but  the 
unbound  fractions  are  increased.  The  alterations  in  steroid  metabolism  are 
corrected by restoration of the euthyroid state (Brenta GA, et al, Variations of 
SHBG in thyroid dysfunction, 1999).
Effects of hypothyroidsm on the GnRH pulsatality. 
TSH  is  secreted  by  the  pituitary  and  its  excess  production  causes 
menstrual abnormality due to its adverse effects on the GnRH pulse generator 
and  not  by  directly  affecting  the  ovary.  When  there  is  decrease  in  GnRH 
pulsatality, anovulation can occur. Even slight changes in pulsatality may result 
in luteal phase defect (Del Pozo, 1979 and Warfel W, 1992).
Primary hypothyroidism and hyperprolactinemia
Hyperprolactinemia  and anovulation  may  be  associated  with  primary 
hypothyroidism.  Remarkable  enlargement  of  the  pituitary  with  thyrotroph 
hyperplasia and hyperprolactinemia is frequently seen in long standing primary 
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hypothyroidism (Franks et al, 1975).
A number of mechanisms may be involved:
1) The  clearance  of  prolactin  tends  to  be  decreased  in  hypothyroidism 
(Warfel W, 1992).
2) Patients with severe hypothy+roidism may have elevated total and free 
estradiol levels giving rise to increased prolactin production stimulated 
by excess free oestrogen. (Tolis G et al, 1979).
3) The third and the most significant mechanism involves the inhibitory 
effects of T3 on TRH production and on TRH receptor expression. A 
decrease in the T3 feedback in hypothyroidism may induce an increase 
in  the  hypothalamic  TRH  production  and  in  the  number  of  TRH 
receptors in the lactotroph. Increased TRH action on the lactotroph in 
turn may stimulate prolactin secretion (Collu R, 1986).
The  duration  of  hypothyroidism  is  important  with  regard  to  the 
mechanism of  amenorrhea   the longer  the  duration,  the higher the 
incidence of amemorrhea and higher the prolactin levels. This may be 
associated  with  decreasing  hypothalamic  content  of  dopamine  with 
ongoing  hypothyrodism.  This  would  lead  to  an  unopposed  TRH 
stimulatory effect on the pituitary cells that secrete prolactin. Constant 
stimulation  by  the  hypothalamic  releasing  hormones  can  result  in 
hypertrophy or hyperplasia of the pituitary (Keye) WR,1976).
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Subclinical Hypothyroidism
This term designates a situation in which an asymptomatic patient has a 
low normal  FT4I  (free  thyroxine  index)  but  a  slightly  elevated  serum TSH 
level.  The TSH elevation in these patients  is modest with values typically 
between 5 and 15 mu/L.  It occurs in 7-10% of women.
Effects of Hyperthyroidism on Reproductive function
The two primary causes of hyperthyroidism are Grave's disease (toxic 
diffuse  goiter)  and Plummer's  disease  (toxic  nodular  goiter)  (Lazarus  JH in 
Lancet  349,1997).   Thyrotoxicosis  in  early  life  may  cause  delayed  sexual 
maturation  although  physical  development  is  normal  and  skeletal  growth 
maybe  accelerated  Menstural  changes  associated  with  hyperthyroidism  are 
unpredictable, ranging from amenorrhea to oligomenorrhea and normal cycles. 
The intermenstrual interval maybe prolonged or shortened, menstrual flow is 
initially  diminished  and  ultimately  ceases  (McKenzie  JM,  1979).   Fertility 
maybe  reduced  and  the  risk  of  miscarriage  is  increased.  In  some  patients 
menstrual cycles are predominantly anovulatory with oligomenorrhea.  In most 
patients,  however,  ovulation  occurs  as  is  indicated  by  the  secretory 
endometrium (Reid RL, 1987).  Hyperthyroidism seldom causes amenorrhea 
unless exophthalmos is present.
The mechanisms involved may be the following.
(1) Increased SHBG levels  decrease the clearance of testosterone and 
estradiol. Increased peripheral aromatisation of androgens gives rise 
to oestrogens due to the increase in peripheral blood flow (Thomas 
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R, 1987).
(2) Another more likely mechanism is the disruption in the amplitude 
and frequency of LH /FSH pulses due to thyroid hormone influences 
on GnRH signalling (DeGroot N, 1979).
Subclinical Hyperthyroidism
The  presence  of  a  chronically  sepressed  serum  TSH  level  with 
peripheral  free  thyroid  hormones  in  the  normal  range  is  called  subclinical 
hyperthyroidism.  The incidence is 0.9%.  Progression to overt hyperthyroidism 
is uncommon.  The incidence increases in older women (Felicetta JU, 1987).
Screening for primary hypothyroidism
Only  a  few  patients  with  amenorrhea/  galactorrhea  will  have 
hypothyroidism that is not clinically apparent.  Although it seems extravagant 
to measure the TSH in such a large number of patients for such a small return, 
because the treatment of hypothyroidism is so simple and is  rewarded by a 
prompt return of menstrual cycles, TSH measurement is warranted (Caldwell 
G, 1985).
The  high  incidence  of  hypothyroidism in  women,  particularly  if  the 
7-10% prevalance of subclinical hypothyroidism is included raises the issue of 
whether  the  cost  of  systematic  periodic  screening  of  an  asymptomatic 
population is justified (Westman AP, BMJ, 1997). The conclusions depend to a 
great  extent,  on  the  assumptions  regarding  the  effectiveness  and  economic 
value  of  therapy  in  asymptomatic  patients  with  TSH elevation  alone.   An 
assessment of TSH levels at 5 year intervals in older women (greater than 50 
26
years)  seems  justified,  but  further  analysis  of  more  extensive  screening 
programs are in order (P. Reid Larsen and Terry F. Davies, 2003).
Prediction of disease onset
Patients  with  increased  TSH and  normal  T4 levels  progress  to  overt 
thyroid failure at a rate of about 5% per year if thyroid auto antibody levels are 
elevated.  If the serum TSH alone is elevated witout positive thyroid antibody 
titres, the annual risk for hypothyroidism drops to approximately 3% per year. 
Most  clinicians  therefore  treat  women  who  have  elevated  serum  TSH 
concentrations  and  positive  thyroid  antibody  tests  even  in  the  absence  of 
symptoms. (Vanderpump MPJ, Turnbridge WMG, 1996).
Thyroid dysfunction and menstrual disturbances in specific conditions
1) Anorexia nervosa
The various problems associated with anorexia represent a dysfunction 
of the body mechanisms regulated by the hypothalamus.  Anorexics are usually 
amenorrhic.   Many  symptoms  can  be  explained  by  the  state  of  relative 
hypothyroidism.   There  appears  to  be  a  compensation  for  the  state  of 
malnourishment with diversion from the formation of active T3 to the inactive 
metabolite  reverse  T3 -  a  state  of  chemical  hypothyroidism  (Herzog  DB, 
Copeland PM, 1985)
2) Exercise and stress induced amenorrhea
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In patients with exercise induced amenorrhea, there is a decrease in the 
frequency of GnRH pulses which is assessed by measuring a decrease in the 
frequency of LH pulses (Olson BR, 1989).  Atheletes have relatively low T4 
levels  but amenorrhic atheletes  have an overall  supression of  all  circulating 
thyroid  hormones  including  reverse  T3.   These  patients  are  usually 
hypoestrogenic,  but  less  severe  alterations  may  cause  minimal  menstrual 
dysfunction (anovulation / luteal phase defect) (Gennazzani AR et al, 1991).
3) Turners Syndrome
Patients with Turners, characterised by 45 XO Karyotype have a short 
stature,  primary amenorrhea and other abnormalities.   A high prevalance of 
autoimmune thyroid disorders is noted.  Approximately 50% of adult patients 
with  Turners  have  anti-thyroid  peroxidase  (anti-TPO)  and antithyroglobulin 
(anti  TG)  antibody.   Approximately  30%  will  develop  subclinical/  clinical 
hypothyroidism (Barbesino G et al, 1998).
4) Postpartum thyroiditis
Transient thyrotoxicosis may develop within 3-6 months after delivery 
and is often followed by a period of hypothyroidism of several months duration 
with an eventual return to euthyroid state (Amino N, 1982).  In some patients, 
only a  hypothyroid phase  is  apparent.   Data  suggest  that  8-10% of women 
experience thyroiditis in the postpartum period (Hayslip et al, 1988). Pregnancy 
is  therefore  an important  risk factor  with transient  thyroiditis  developing in 
some patients and thyroid failure developing permanently or in the early years 
after pregnancy in a significant proportion.
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MATERIALS AND METHODS
The present study of "Thyroid Profile in AUB" was conducted in Govt. 
R.S.R.M.  Lying-in  Hospital,  attached  to  Govt.  Stanley  Medical  College, 
Chennai.  This is a cross-sectional study of 250 women with AUB, based on 
data collected from women with AUB attending the out-patient department and 
in-patients during a period of 8 months from May 2005 to December 2005 at 
this hospital.  The study group included women with the following complaints.
1) Oligomenorrhea : Cycle length greater than 35 days.
2) Hypomenorrhea : Bleeding lasting less than 2 days.
3) Menorrhagia : Blood 
loss greater than 60 ml or more than  6 pads / 
day associated with  clots.
4) Polymenorrhea : Cycle length less than 22 days.
5) Amenorrhea : Absence 
of  menstruation  for  6  months  or  3 
consecutive menstrual cycles.
Inclusion Criteria
(1) Women in the age group of 18-45 years.
(2) Women with any of the menstrual disturbances mentioned above.
(3) Women who do not have signs  of  demonstrable pelvic  pathology 
including PID.
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(4) Women with increased BMI.
(5) Women who are not on any hormonal preparation.
(6) Women who were not using any IUCD in the past two years.
(7) Women who have not had any thyroid replacement therapy.
(8) Women with signs and symptoms of hypo/ hyperthyroidism.
Exclusion Criteria
(1) Teenage AUB.
(2) Age greater than 45 years.
(3) Presence  of  palpable  pelvic  pathology  like  fibroids,  polyps  or 
cervical growths.
(4) Presence of general disorders like tuberculosis.
(5) Presence of diabetes, hypertension or clotting abnormalities .
(6) Patients with history of bleeding diatheses.
(7) Patients  on  drugs  like  aspirin,  heparin,  sulpha  drugs,  antithyroid 
medication, eltroxin, glucocorticoids, and amiodarone.
Symptoms and Signs of hyperthyroidism.
(1) Weight loss greater than 10 kg in 3 months or subjective weight loss
(2) Diarrhoea
(3) Heat intolerence
(4) Tremors
(5) Tachycardia
(6) Eye changes - exophthalmos
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Symptoms and signs of hypothyroidism
(1) Weight gain of more than 10 kg in 3 months or subjective weight 
gain 
(2) Constipation
(3) Slow mentation / lethargy / increased sleepiness.
(4) Elevated cholesterol
(5) Coarse skin.
PROCEDURE
Patients were selected based on the above criteria and history was taken 
as  per  the  proforma  including  a  detailed  menstrual  history  and  questions 
regarding the signs  and symptoms,  of  hypothyroidism and hyperthyroidism. 
The following examination was done.
A detailed general examination focussing specifically on the presence/ 
absence  of  anaemia,  thyroid  swelling,  cardiovascular  abnormality,  gross 
nervous system dysfunction, galactorrhea and abnormal hair distribution.  The 
height  in  centimeters  and  weight  in  kilograms was  measured  and the  BMI 
calculated.  An abdominal, speculum examination and pelvic examination were 
done to rule out  other causes of abnormal bleeding. 5 ml of venus blood was 
taken in a dry plain glass container without any anticoagulant for TSH assay 
and T4 estimation. Morning sample in the fasting state was taken.
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TSH assay was performed using ultrasensitive solid phase-two site 
immunoradiometric assay (IRMA). IRMA-K9 kit supplied by Board of Radiation and 
Isotope Technology (BRIT), Bombay was used.  The physiological range was 0.3 - 
6.18 µIU/ml with due consideration given to dional / pulsatile variation.
T4 was analysed using RIA K-5/5A kit supplied by BRIT, Bombay.  The 
physiological range was 4.8 to 11.5 µg / dl.
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ANALYSIS OF THE STUDY - OBSERVATIONS
TABLE - 1
AGE DISTRIBUTION OF THE STUDY GROUP
Age group Frequency Percentage
18-24 32 12.8%
24-32 142 56.8%
32-40 51 20.4%
>40 25 10%
Majority of the patients belonged to the age group of 24 - 32 years
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TABLE - 2
PARITY OF THE STUDY GROUP
Parity Frequency Percentage
Nullipara 23 9.2%
P1L1 65 26%
P2L2 112 44.8%
Multipara 50 20%
Majority of the patients in the study group were P2L2
TABLE - 3
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Parity of the study group
9.20%
26%
44.80%
20%
Nullipara P1L1 P2L2 Multipara
TYPE OF AUB
Type of AUB Frequency Percentage
Oligomenorrhea 78 31.2%
Menorrhagia 110 44.0%
Amenorrhea 78 19.6%
Hypomenorrhea 7 2.8%
Polymenorrhea 6 2.4%
Majority of patients in the study group had menorrhagia and 
oligomenorrhea
TABLE - 4
DURATION OF AUB
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Percentage 31.20% 44.00% 19.60% 2.80% 2.40%
Oligomenorrhea Menorrhagia Amenorrhea Hypomenorrhea Polymenorrhea
AUB Duration Frequency Percentage
1-3 months 97 38%
4-6 months 82 32.8%
7 months - 1 year 40 16.0%
1-3 years 23 9.2%
>3 years 2 0.8%
Since menarche 6 2.4%
Majority of the patients presented with AUB of 1-6 months duration
TABLE - 5
FREQUENCY OF AUB
No.of Episodes Frequency Percentage
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Duration of AUB
Duration of AUB
Percentage 38% 32.80% 16.00% 9.20% 0.80% 2.40%
1-3 months 4-6 months 7mths - 1 year 1-3 years >3 years Since menarche
First episode 193 77.2%
Second episode 28 11.2%
Third episode 16 6.4%
Fourth episode 6 2.4%
Fifth episode 4 1.6%
Sixth episode 3 1.2%
Majority of the patients presented at the first episode itself.
Only a minority reported after the fourth episode.
TABLE - 6
GENERAL EXAMINATION
General Examination Number Percentage
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Percentage 77.20% 11.20% 6.40% 2.40% 1.60% 1.20%
First episode Second episode Third episode Fourth episode Fifth episode Sixth episode
Normal 197 78.8%
Anaemia 44 17.6%
Thyromegaly 9 3.6%
21% of the patients  had abnormal  findings on examination.  80% were 
normal.
TABLE - 7
BMI - BODY MASS INDEX
BMI Range Number Percentage
< 18 (Lean) 6 2.4%
18-24 (Normal) 179 71.6%
25-29 (Overweight) 48 19.2%
30-34 (Obese) 12 4.8%
>34 (Morbid Obesity) 5 2.0%
6.8% of the patients were obese.
TABLE - 8
GYNAEC EXAMINATION
Size of the Uterus Number Percentage
Normal Size 216 86.4%
Bulky 34 13.6%
TABLE - 9
ULTRASONOGRAM
USG Findings Number Percentage
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Not done 208 83.2%
Bulky Uterus 13 5.2%
Cystic ovaries 29 11.6%
TABLE - 10
FRACTIONAL CURETTAGE
Endometrial Histology Number Percentage
Not done 224 89.6%
Secretory 15 6.0%
Proliferative 11 4.4%
TABLE - 11
HAEMOGLOBIN ESTIMATION
Haemoglobin (gm%) Number Percentage
<9 gm% 40 16.0%
>9 gm% 172 68.8%
Not done 38 15.2%
TABLE - 12
SIGNS AND SYMPTOMS OF HYPOTHYROIDISM
Signs/symptoms Number Percentage
Nil 175 70%
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Constipation 19 7.6%
Cold intolerance 1 0.4%
Voice change 11 4.4%
Weight gain 31 12.4%
Lethargy 12 4.8%
Palpitation 1 0.4%
70%  of  patients  had  no  symptoms  /  signs  of  hypothyroidism. 
Weight gain was the most frequent symptom seen in 12.4% followed by 
constipation in 7.6%.
TABLE - 13
SIGNS AND SYMPTOMS OF HYPERTHYROIDISM
Signs / Symptom Number Percentage
Nil 132 52.8%
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Signs and Symptoms of Hypothyroidism
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Percentage 70% 7.60% 0.40% 4.40% 12.40% 4.80% 0.40%
Nil Constipation Cold intolerance Voice change Weight gain Lethargy Palpitation
Heat intolerance 4 1.6%
Anxiety 12 4.8%
Weight Loss 22 8.8%
Fatigue 71 28.4%
Tremors 6 2.4%
Diarrhoea 3 1.2%
About  53%  of  the  patients  had  no  signs  /  symptoms  of 
hyperthyroidism. The most common symptom was fatigue seen in 28.4%.
TABLE - 14
T4 VALUES (N 4.8 -11.5 µg/dl)
T4 (µg/dl) Number Percentage
<4.8 34 13.6%
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Signs and Symptoms of Hyperthyroidism
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Percentage 52.80% 1.60% 4.80% 8.80% 28.40% 2.40% 1.20%
Nil Heat intolerance Anxiety Weight Loss Fatigue Tremors Diarrhoea
4.8 - 11.5 199 79.6%
>11.5 17 6.8%
TABLE - 15
TSH VALUES (N 0.3 - 6.18 µIU/ml)
TSH (µIU/ml) Number Percentage
<0.3 23 9.2%
0.3 - 6.18 182 72.8%
>6.18 45 18.0%
TABLE - 16
AMENORRHEA - AGE DISTRIBUTION
Age group (years) Number Percentage
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Distribution of T4 and TSH Values
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T4 13.60% 79.60% 6.80%
TSH 9.20% 72.80% 18.00%
< Normal Normal >Normal
18 - 24 7 14.28%
24 - 32 21 42.86%
32 - 40 18 36.73%
>40 3 6.12%
TABLE - 17
AMENORRHEA - PARITY DISTRIBUTION
Parity Number Percentage
Nullipara 8 16.3%
P1L1 10 20.41%
P2L2 24 48.98%
Multipara 7 14.28%
TABLE - 18
AMENORRHEA - T4 VALUES (N 4.8 -11.5 µg/dl)
T4 (µg/dl) Number Percentage
<4.8 9 18.37%
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4.8 - 11.5 33 67.35%
>11.5 7 14.29%
TABLE - 19
AMENORRHEA - TSH VALUES (N 0.3 -6.18 µIU/ml)
TSH (µIU/ml) Number Percentage
<0.3 8 16.33%
0.3 - 6.18 31 63.27%
>6.18 10 20.41%
TABLE - 20
MENORRHAGIA - AGE DISTRIBUTION
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Amenorrhea - T4 and TSH Values
T4 18.37% 67.35% 14.29%
TSH 16.33% 63.27% 20.41%
< Normal Normal > Normal
Age group (years) Number Percentage
18 - 24 11 10%
24 - 32 86 78.18%
32 - 40 5 4.55%
> 40 8 7.27%
TABLE - 21
MENORRHAGIA - PARITY DISTRIBUTION
Parity Number Percentage
Nullipara 3 2.73%
P1L1 21 19.09%
P2L2 57 51.82%
Multipara 29 26.36%
TABLE - 22
MENORRHAGIA - T4 VALUES (N 4.8 - 11.5 µg/dl)
T4 (µg/dl) Number Percentage
<4.8 12 10.90%
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4.8 - 11.5 98 89.09%
>11.5 - -
TABLE - 23
MENORRHAGIA - TSH VALUES (N 0.3 -6.18 µIU/ml)
TSH (µIU/ml) Number Percentage
<0.3 - -
0.3 - 6.18 88 80%
>6.18 22 20%
TABLE - 24
OLIGOMENORRHEA - AGE DISTRIBUTION
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Menorrhagia - T4 and TSH Values
T4 10.90% 89.09% 0%
TSH 0.00% 80% 20%
< Normal Normal > Normal
Age group (years) Number Percentage
18 - 24 12 15.38%
24 - 32 32 41.02%
32 - 40 24 30.76%
>40 10 12.18%
TABLE - 25
OLIGOMENORRHEA - PARITY DISTRIBUTION
Parity Number Percentage
Nullipara 15 19.3%
P1L1 26 33.33%
P2L2 34 43.58%
Multipara 3 3.84%
TABLE - 26
OLIGOMENORRHEA - T4 VALUES (N 4.8 - 11.5 µg/dl)
T4 (µg/dl) Number Percentage
<4.8 9 11.5%
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4.8 - 11.5 56 71.8%
>11.5 13 16.66%
TABLE - 27
OLIGOMENORRHEA - TSH VALUES (N 0.3 -6.18 µIU/ml)
TSH (µIU/ml) Number Percentage
<0.3 11 14.1%
0.3 - 6.18 53 67.94%
>6.18 14 17.94%
TABLE - 28
POLYMENORRHEA - AGE DISTRIBUTION
Age group (years) Number Percentage
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Oligomenorrhea - T4 and TSH Values
T4 11.50% 71.80% 16.66%
TSH 14.10% 68% 17.94%
< Normal Normal > Normal
18 - 24 2 33.33%
24 - 32 2 33.33%
32 - 40 - -
>40 2 33.33%
TABLE - 29
POLYMENORRHEA - PARITY DISTRIBUTION
Parity Number Percentage
Nullipara - -
P1L1 2 33.33%
P2L2 3 50%
Multipara 1 16.66%
TABLE - 30
POLYMENORRHEA - T4 VALUES (N 4.8 - 11.5 µg/dl)
T4 (µg/dl) Number Percentage
<4.8 - -
4.8 - 11.5 6 100%
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>11.5 - -
TABLE - 31
POLYMENORRHEA - TSH VALUES (N 0.3 -6.18 µIU/ml)
TSH (µIU/ml) Number Percentage
<0.3 - -
0.3 - 6.18 5 83.33%
>6.18 1 16.66%
TABLE - 32
STUDENT 't' TEST WITH 5% LEVEL OF SIGNIFICANCE
Sl.No. Variable Chi Square (χ2) P Value (95% confidence interval)
1. Age 4.73 0.019 Significant
2. Parity 1.86 0.60 Not Significant
3. Type of AUB 7.64 0.10 Not Significant
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Polymenorrhea - T4 and TSH Values
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T4 0.00% 100.00% 0.00%
TSH 0.00% 83.33% 16.66%
< Normal Normal > Normal
4. Duration of AUB 12.96 0.02 Significant
5. Number of episodes 10.76 0.3 Significant
6. General Examination 15.82 0.001 Significant
7. Body Mass Index 18.65 0.001 Significant
8. Gynaec Examination 0.63 0.24 Not Significant
9. USG 1.40 0.49 Not Significant
10. Haemoglobin 0.40 0.53 Not Significant
11. T4 4.03 0.05 Significant
12. TSH 4.13 0.03 Significant
TABLE -33
T4 vs TSH AS A SCREENING TEST
Sensitivity 72% (60 - 82%)
Specificity 100% (98 - 100%)
Positive Predictive Value 100% (92 - 100%)
Negative Predictive Value 91% (85 - 94%)
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DISCUSSION
AUB is a benign yet debilitating disease with a strong association with 
thyroid  disorders.   Our  study  highlights  the  association  between  AUB and 
thyroid  dysfunction  by  measurement  of  T4 and  TSH in  the  fasting  state  in 
women with AUB.
Hypothyroidism is observed in 8.8% of women with menorrhagia, and 
4.0% of women with amenorrhea. Hyperthyroidism is seen in 5.6% of women 
with oligomenorrhea.  The overall incidence of thyroid dysfunction is 20.4%. 
This correlates with the study by Wilansky et al, 1992.
Study Incidence of thyroid disorders
Prentice et al, 1999 36%
Wilansky et al, 1992 22%
Present study 20.4%
Some patients have a normal serum TSH despite low T3 and T4.  This is 
explained by a downward resetting of the threshold for TSH inhibition TSH 
setpoint for a particular serum T3, T4 increases with age and is also altered by 
personal  and  familial  character.   TSH values  tend  to  change  more  rapidly 
because the half life of TSH is much shorter than T3 and T4.  This should be 
considered  with  regard  to  abnormal  relationships  between T3,  T4 and  TSH. 
There  are  some variations  which  should  be  given  due  consideration  before 
interpreting the results.
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1) T4-Methodology, pregnancy
2) TSH - diurnal variation, pulsatile secretion.
Alteration in the relationship between T4 and TSH can be caused by alternate 
thyroid stimulating  hormones  like  TSH isoforms,  chorionic  gonadotrophins, 
and TSH receptor stimulating antibody.  It  can be caused by hormones and 
drugs like glucocorticoids, severe non-thyroidal illness,  recent thyrotoxicosis 
and long standing hypothyroidism.  The incidence of thyroid dysfunction in the 
reproductive age group is 1-2%. It is 10 times more common in women than in 
men. The incidence of thyroid dysfunction in a population with AUB is 20.4% 
according to our study and hence selective screening of this population would 
result in a higher yield.
A major benefit of routine testing is the earlier detection of unsuspected 
overt thyrotoxicosis or subclinical hypothyroidism or hyperthyroidism.  Most 
clinicians advocate treatment of women with elevated TSH levels in view of 
risk of hypothyroidism developing subsequently.
The ACOG has recommended screening with sensitive TSH-assay in 
asymptomatic women over the age of 40 years.  TSH assay meets the WHO 
criteria for a screening test.
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(1) The condition should pose an important health problem.
(2) Natural history of the disease should be well understood.
(3) There should be a recognisable early stage.
(4) Treatment of the disease at an early stage should be of more benefit 
than treatment started at a later stage.
(5) There should be a suitable test.
(6) The test should be acceptable to the population.
(7) There should be adequate facilities for treatment of the abnormality 
detected.
(8) It should be cost effective.
(9) The chances of physical and psychological harm to those screened 
should be less than the benefit.
The TSH assay can also be used as a management and prognostic tool 
besides its use in diagnosis and screening.
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SUMMARY
The  present  study  is  a  cross-sectional  study  of  250  women  with 
abnormal  uterine  bleeding  in  the  reproductive  age  group  undertaken  in  a 
tertiary referral hospital over a period of 8 months.  It was done to ascertain the 
possibility of a correlation between subclinical thyroid dysfunction and AUB.
The  history  was  elicited  according  to  the  proforma.  Anthropometric 
measurement were taken and a detailed examination was done.  T4 and TSH 
levels were evaluated in the fasting   rate and the results interpreted.
1) The  study  showed  a  significant  correlation   (p=  0.019,  significant) 
between increasing age and thyroid dysfunction.
2) There was a significant correlation with the duration of AUB (p=0.02) 
and the number of episodes (p=0.03).
3) However there was no correlation with parity or the type of AUB.
4) The  general  examination  and  body  mass  index  showed  a  significant 
correlation (p=0.001).
5) The  USG  and  haemoglobin  estimation  did  not  show  a  significant 
correlation.
6) TSH is a good screening test with a sensitivity of 72% and specificity of 
100%.  The positive and negative predictive value  were 100% and 91% 
respectively.  
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7) The findings of our study can be summarised as follows :
Incidence of hypothyroidism 13.6%
Incidence of hyperthyroidism 6.8%
In the different types of AUB:
hyperthyroidism 5.6%
a. Oligomenorrhea
hypothyroidism 4.4 %
hyperthyroidism 3.2%
b. Amenorrhea
hypothyroidism 4.0 %
hyperthyroidism 
c. Menorrhagia
hypothyroidism 8.8 %
hyperthyroidism 
d. Polymenorrhea
hypothyroidism 0.4 %
The incidence of thyroid disorders in polymenorrhea is low due to the 
higher incidence of PID in this group of patients(exclusion criterion).
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CONCLUSION
It may be concluded from the present study that there is a significant 
association between  thyroid disorders and AUB. The high incidence of thyroid 
disorders  in  women  with  AUB,  particularly  if  the  7-10%  of  subclinical 
hypothyroidism is  included,  justifies  the  cost  of  screening  in  this  selective 
population.  The risk of  progression to  overt  hypothyroidism (about  5% per 
year)  in  patients  with  subclinical  disease  and  the  cost-benefit  ratio  also 
emphasise the need for selective screening.
Early detection of subclinical disease by selective screening facilitates 
appropriate therapy early in the course of the disease.
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PROFORMA
Name Age Address
Sex Parity
Sterilisation
H/O O/E
Menorrhagia General Condition
Oligomennorrhea Anaemia
Amenorrhea Thyromegaly
Polymenorrhea BMI
Others P/A
S/E
P/V
H/O S/S Hyperthyroidism Thyroid Function tests
______________________ T4
______________________ TSH
______________________ Inference
H/O S/S Hypothyroidism Other Investigations
_____________________ Hb in gm/dl
_____________________ USG
_____________________ Fractional Curettage
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ABBREVIATIONS
AUB - Abnormal Uterine Bleeding
T4 - Thyroxine
T3 - Tri-iodothyronine
TSH - Thyroid Stimulating Hormone
TRH - Thyrotropin Releasing Hormone
LH - Luteinising Hormone
FSH - Follicle Stimulating Hormone
hCG - human Chorionic Gonadotrophin
TR - Thyroid hormone Receptor
RXR - Retinoid X Receptor
RT3 - Reverse T3
TBG - Thyroid Binding Globulin
SHBG - Sex Hormone Binding Globulin
FT4 - Free Thyroxine
TT4 - Total Thyroxine
GnRH - Gonadotrophin Releasing Hormone
Anti TPO - Anti Thyroid Peroxidase
Anti TG - Anti Thyroglobulin
BMI - Body Mass Index
PID - Pelvic Inflammatory Disease
IUCD - Intrauterine Contraceptive Device
IRMA - Immuno Radiometric Assay
BRIT - Board of Radiation and Isotope Technology
ACOG - American College of Obstetrics and Gynaecology
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